Substance abuse and movement disorders

Movement Disorders

Volumn 25, Issue 13, 2010, Pages 2010-2020

  Brust, John C M ^a  

^a University College of Physicians and Surgeons ^*  (United States)

Author keywords

Ethanol; Heroin; Meperidine; Myoclonus; Psychostimulant

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE DERIVATIVE; ANXIOLYTIC AGENT; CANNABIS; COCAINE; DIAMORPHINE; OPIATE DERIVATIVE; PETHIDINE; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT;

ACUTE TOXICITY; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; CHOREA; DYSTONIA; ESSENTIAL TREMOR; FLAPPING TREMOR; HUMAN; INHALANT ABUSE; LEUKOENCEPHALOPATHY; MOTOR DYSFUNCTION; MYOCLONUS; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SLEEP; SUBSTANCE ABUSE; TOBACCO;

HUMANS; MOVEMENT DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 78649350162     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22599     Document Type: Review

References (176)

1. Brust JCM. Neurological aspects of substance abuse, 2nd ed. Boston: Butterworth-Heinemann, 2004, p 334-340.
2. Neiman J, Lang AE, Fornazarri L, Carlen PL. Movement disorders in alcoholism. A review. Neurology 1990;40:741-746
3. Carrie JRG. Finger tremor in alcoholic patients. J Neurol Neurosurg Psychiatry 1965;28:529-532.
4. LeFebvre-D'Amour M, Shahani BT, Young RR. Tremor in alcoholic patients. Prog Clin Neurophysiol 1978;6:160-168.
5. Koller W, O'Hara R, Dorus W, et al. Tremor in chronic alcoholism. Neurology 1985;35:1660-1662.
6. Kraus ML, Gottleig LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985;313:905-909.
7. Gallimberti L, Gentile N, Cibin M, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-789.
8. Kominger C, Roller RE, Lesch OM. Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital. Acta Med Austriaca 2003;30:83-86.
9. Cardoso F, Jankovic J. Movement disorders in neurologic complications of drug and alcohol abuse. Neurol Clin 1993;11: 625-638.
10. Aisen ML, Adelstein BD, Romero J, et al. Peripheral mechanical loading and the mechanism of the tremor of chronic alcoholism. Arch Neurol 1992;49:740-742
11. Carlen PL, Lee MA, Jacob M, et al. Parkinsonism provoked by alcoholism. Ann Neurol 1981;9:84-86.
12. Lang AE, Marsden CD, Obeso JA, et al. Alcohol and Parkinson disease. Ann Neurol 1982;12:254-256.
13. Neiman J, Borg S, Wahlund LO. Parksinsonism and dyskinesias during ethanol withdrawal. Br J Addict 1988;83:437-439.
14. Shen WW. Extrapyramidal symptoms associated with alcohol withdrawal. Biol Psychiatry 1984;19:1037-1043.
15. Shandling M, Carlen PL, Lang AE. Parkinsonism in alcohol withdrawal. A follow-up study. Mov Disord 1990;5:36-39.
16. Fornazzari L, Carlen PL. Transient choreiform dyskinesias during alcohol withdrawal. Can J Neurol Sci 1982;9:89-90.
17. Mullin PJ, Kershaw PW, Bolt JMW. Choreoathetotic movement disorder in alcoholism. Br Med J 1970;4:278-281.
18. Darden JH, Hunt WA. Reduction of striatal dopamine release during an ethanol withdrawal syndrome. J Neurochem 1977;29: 1143-1145.
19. Balldin J, Alling C, Gottfries CG, et al. Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology 1985;86:142-146.
20. Lutz EG. Neuroleptic-induced akathesia and dystonia triggered by alcohol. JAMA 1976;236:2422-2423.
21. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16:57-66.
22. Drake ME, Jr. Recurrent spontaneous myoclonus in alcoholic withdrawal. South Med J 1983;76:1040-1042.
23. Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis 1953; 32:198-237.
24. Weinreb WH, Perry RJ, Jenkyn LR. Rhythmic alternating asterixis. J Neurol Neurosurg Psychiatry 1982;45:857-858.
25. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine ligands. Pharmacol Rev 1991;43:27-71.
26. Layargues GP. Movement dysfunction and hepatic encephalopathy. Metab Brain Dis 2001;16:27-35.
27. Klebe S, Stolze H, Grensing K, et al. Influence of alcohol on gait in patients with essential tremor. Neurology 2005;65: 96-101.
28. Sinclair JG, Lo GF, Harris DP. Ethanol effects on the olivocerebellar system. Can J Physiol Pharmacol 1982;60:610-614.
29. Boeker H, Wills AJ, Ceballes-Baumann A, et al. The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol 1996;39:650-658.
30. Zeuner KE, Molley FM, Shoge RO, et al. Effect of ethanol on the central oscillator in essential tremor. Mov Disord 2003;18: 1280-1285.
31. Koller WC. Alcoholism in essential tremor. Neurology 1983; 33:1074-1076.
32. Schroeder D, Nasrallah HA. High alcoholism rate in essential tremor patients. Am J Psychiatry 1982;139:1471-1473.
33. Bacsi AM, Halmagyi GM, Colebatch JG. Sway patterns in a case of orthostatic tremor responsive to alcohol. Mov Disord 2004;19:1459-1463.
34. Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 2002;59: 1187-1196.
35. Han F, Lang AE, Racacho L, et al. Mutations in the epsilonsarcoglycan gene found to be uncommon in seven myoclonusdystonia families. Neurology 2003;61:244-246.
36. Vidailhet M, Tassin J, Nivelon-Chevallier A, et al. A major locus for several phenotypes of myoclonus-dystonia on chromosome 7q. Neurology 2001;56:1213-1216.
37. Borges V, Ferraz HB, Andrade LA. Alcohol-sensitive hereditary essential myoclonus with dystonia: a study of six Brazilian patients. Neurol Sci 2000;21:373-377.
38. Saunders-Pullman R, Schriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002;58:242-245.
39. Frucht SJ, Bordelon Y, Houghton WH, et al. Marked amelioration of alcohol-responsive posthypoxic myoclonus by gammahydroxybutyric acid (Xycem). Mov Disord 2005;20:745-751.
40. Jain S, Tamer SK, Hiran S. Beneficial effect of alcohol in hereditary cerebellar ataxia with myoclonus (progressive myoclonic ataxia): report of two siblings. Mov Disord 1996;11:751-752.
41. Kriesel SH, Binder J, Wohrle JC, et al. Dystonia in the Mohr Tranebjaerg syndrome responds to GABA-ergic substances. Mov Dis 2004;19:1241-1243.
42. Lossos A, Cohen O. Meimer V, et al. Intrafamilial heterogeneity of movement disorders: report of three cases in one family. J Neurol 1997;244:426-430.
43. Bartolomei F, Azulay J-P, Barrie M, et al. Myoclonic alcoholic epilepsy. Epilepsia 1996;37:406-409.
44. Landolt HP, Barbely AA. Alcohol and sleep disorders. Ther Umsch 2000;57:241-245.
45. Gann H, Feige B, Fasihi S, et al. Periodic limb movements during sleep in alcohol dependent patients. Eur Arch Psychiatry Clin Neurosci 2002;252:124-129.
46. Warner GT, McAuley JH. Alcohol-induced paroxysmal nonkinesogenic dyskinesia after pallidal hypoxic insult. Mov Disord 2003;18:455-456.
47. Lance JW. Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes. Ann Neurol 1977;2: 285-293.
48. Lutz EG. Neuroleptic-induced akathisia and dystonia triggered by alcohol. JAMA 1976;236:2422-2423.
49. Freed E. Alcohol-triggered neuroleptic-induced tremor, rigidity and dystonia. Med J Aust 1981;2:44-45.
50. Setta F, Jacquy J, Hildebrand J, et al. Ataxia induced by small amounts of alcohol. J Neurol Neurosurg Psychiatry 1998;65: 370-373.
51. Gallinberti L, Spella MR, Soneini CA, et al. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000;20:257-262.
52. Frucht SJ, Bardelon Y, Houghton WA, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005;20:1330-1337.
53. Craig K, Gomez HF, McManus JL, et al. Severe gammahydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65-70.
54. Vickers, MD. Gammahydroxybutyric acid. Int Anesth Clin 1969;7:75-79.
55. Khantzian EJ, McKenna GJ. Acute toxic and withdrawal reactions associated with drug use and abuse. Ann Intern Med 1979;90:361-372.
56. Madrak LN, Rosenberg M. Zolpidem abuse. Am J Psychiatry 2001;158:1330-1331.
57. Anderson SN, Skullerud K. Hypoxic/ischemic brain damage, especially pallidal lesions, in heroin addicts. Forensic Sci Int 1999;102:51-59.
58. Vila N, Chamarro M. Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases. Clin Neurol Neurosurg 1997;99:259-262.
59. Schoser BG, Groden C. Subacute onset of oculogyric crisis and generalized dystonia following intranasal administration of heroin. Addiction 1999;94:431-434.
60. Miller JM, Vorel SR, Tranguch AJ, et al. Anhedonia after a selective bilateral lesion of the globus pallidus. Am J Psychiatry 2006;163:786-788.
61. Lauterbach EC. Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Clin Neuropharmacol 1999;22:87-92.
62. Isoardo G, Zibetti M, Troni W. Myoclonus of probable spinal origin as a potential side effect of tramadol. A case report. J Neurol 2005;252:852.
63. Potter JM, Reid DB, Shaw RJ, et al. Myoclonus associated with treatment with high doses of morphine. The role of supplemental drugs. Br Med J 1989;299:150-153.
64. Hershey LA. Meperidine and central neurotoxicity. Ann Intern Med 1983;98:548-549.
65. Hochman MS. Meperidine-associated myoclonus and seizures in long-term hemodialysis patients. Ann Neurol 1983;14:593.
66. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983;13:180-185.
67. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol 1981;1:319-321.
68. Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. Ann Pharmacol 2002;36:1647-1648.
69. Tissot TA. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. Anesthesiology 2003; 98:1511-1512.
70. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther 2002;9:53-68.
71. Roy S, Fortier L-P. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by vanlafaxine. Can J Anesth 2003;50:32-35.
72. Caplan LR, Thomas C, Banks G. Central nervous system complications of addiction to "T's and Blues." Neurology 1982;32: 623-628.
73. Young RJ. Dextropropoxyphene overdose: pharmacological considerations and clinical management. Drugs 1983;26:70-79.
74. Lieberman AN, Goldstein M. Reversible parkinsonism related to meperidine. N Engl J Med 1985;312:509.
75. Berthier ML, Campus VM, Kulisevsky J, et al. Heroin and malignant coprolalia in Tourette's syndrome. J Neuropsychiatr Clin Neurosci 2003;15:116-117.
76. Wasserman S, Yahr MD. Choreic movements induced by the use of methadone. Arch Neurol 1980;37:727-728.
77. Bonnet U, Banger M, Wolstein J, et al. Choreoathetoid movements associated with rapid adjustment to methadone. Pharmacopsychiatry 1998;31:143-145.
78. Palmer W-R, Haferkame G. Involuntary movements associated with methadone. Arch Neurol 1981;38:737.
79. De Maio D, Caponeri MA, Circhetti V, et al. Sulpiride and extrapyramidal syndromes in chronic heroin addiction. Neuropsychobiology 1978;4:36-39.
80. Kandall SR. Treatment strategies for drug-exposed neonates. Clin Perinatal 1999;26:231-243.
81. Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
82. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
83. Calne DB, Langston JW, Stoessl AJ, et al. Positron emission tomography after MPTP. Observations relating to the cause of parkinson's disease. Nature 1984;317:246.
84. Herkenham M, Little MD, Bankiewiez K, et al. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MRTP administration: an in vivo autoradiographic study. Neuroscience 1991;40:133-158.
85. Przedborski S, Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res 2001;1:407-413.
86. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
87. Wolters EC, van Wijngaarden GK, Stam FC, et al. Leukoencephalopathy after inhaling "heroin" pyrolysate. Lancet 1982;2: 1233-1237.
88. Weber W, Henkes H, Moller P, et al. Toxic spongiform leukoencephalopathy after inhaling heroin vapor. Eur Radiol 1998; 8:749-755.
89. Kriegstein AR, Shungu DC, Millar WS, et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (chasing the dragon). Neurology 1999;53:1765-1773.
90. Bartlett E, Mikulis DJ. Chasing "chasing the dragon" with MRI: leukoencephalopathy in drug abuse. Br J Radiol 2005;78: 997-1004.
91. Heales S, Crawley F, Rudge P. Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency. Mov Disord 2004;19:1248-1251.
92. Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008;63:146-152.
93. Maschke M, Fehlings T, Kastrup O, et al. Toxic leukoencephalopathy after intravenous consumption of heroin and cocaine with unexpected clinical recovery. J Neurol 1999;246: 850-851.
94. Roulet Perez E, Maeder P, Rivier L, et al. Toxic leukoencephalopathy after heroin ingestion in a 21/2-year-old child. Lancet 1992;340:729.
95. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatr 1999;4: 512-523.
96. Randrup A, Munkvad J. Stereotyped activities produced by amphetamine in several species and man. Psychopharmacologia 1967;11:300-310.
97. Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry 1981;44:728-730.
98. Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med 1988;6:131-133.
99. See SJ, Tan EK. Severe amphetamine-induced bruxism: treatment with botulinum toxin. Acta Neurol Scand 2003;107: 161-163.
100. Klawans H, Weiner WJ. The effect of D-amphetamine on choreiform movement disorders. Neurology 1974;24:312-318.
101. Meyerhoff JL, Snyder SH. Gilles de la Tourette disease and minimal brain dysfunction: amphetamine isomers reveal catecholamine correlates in an affected patient. Psychopharmacologia 1973;29:211-220.
102. Golden GS. Gilles de la Tourette's syndrome following amphetamine administration. Dev Med Child Neurol 1976;16:76-77.
103. Pollack MA, Cohen NL, Friedhoff AJ. Gilles de la Tourette's syndrome: familial occurrence and precipitation by methylphenidate therapy. Arch Neurol 1977;34:630-632.
104. Bonthala CM, West A. Pemoline induced chorea and Gilles de la Tourette's syndrome. Br J Psychiatry 1983;143:300-302.
105. Espelin DE, Done AK. Amphetamine poisoning. Effectiveness of chlorpromazine. N Engl J Med 1968;278:1361-1365.
106. Kita T, Wagner GC, Makashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 2003;92:178-195.
107. Moszczynska A, Fitzmaurice P, Ang L, et al. Why is parkinsonism not a feature of human methamphetamine use. Brain 2004;127:363-370.
108. Stephens A, Logina I, Liguts V, et al. A parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008;358:1009-1017.
109. Rylander G. Psychosis and the punding and choreiform syndromes in addictions to central stimulant drugs. Psychiatry Neurol Neurochir 1972;75:203-212.
110. Daras M, Koppel BS, Atos-Radzion E. Coaine-induced choreoathetoid movements (crack-dancing). Neurology 1994;44:751-752.
111. Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry 1999;45: 1630-1635.
112. Scharf D. Opsoclonus-myoclonus following the intranasal use of cocaine. J Neurol Neurosurg Psychiatry 1989;52:1447-1448.
113. Crum RM, Anthony JC. Cocaine use and other suspected risk factors for obsessive-compulsive disorder: a prospective study with data from the epidemiologic catchment area surveys. Drug Alcohol Depend 1993;31:281-295.
114. Derlet RW, Albertson TE. Emergency department presentation of cocaine intoxication. Ann Emerg Med 1989;18:182-186.
115. Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 1990; 88:325-331.
116. Rebischung D, Daras M, Tuchman AJ. Dystonic movements associated with cocaine use. Ann Neurol 1990;28:267-268.
117. Kumor K. Cocaine withdrawal dystonia. Neurology 1990;40: 863-864.
118. Farrell PE, Deihl AK. Acute dystonic reaction to crack cocaine. Ann Emerg Med 1991;20:322.
119. Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology 1989;39:996-997.
120. Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use. South Med J 1997;90:1050-1052.
121. Fines RE, Brady WJ, DeBehnke DJ. Cocaine-associated dystonic reaction. Am J Emerg Med 1997;15:513-515.
122. Weiner WJ, Rubinstein A, Lewin B, et al. Cocaine-induced persistent dyskinesias. Neurology 2001;56:964-965.
123. Hegarty AM, Lipton RB, Merriam AE, et al. Cocaine as a risk factor for acute dystonic reactions. Neurology 1991;41:1670-1672.
124. Kumor K, Sherer M, Jaffe J. Haloperidol-induced dystonia in cocaine addicts. Lancet 1986;2:1341-1342.
125. Mesulam M-M. Cocaine and Tourette's syndrome. N Engl J Med 1986;315:398.
126. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990;40:999-1000.
127. Factor SA, Sanchez-Ramos JR, Wiener WJ. Cocaine and Tourette's syndrome. Ann Neurol 1988;23:423-424.
128. Bauer LO. Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients. Alcohol Clin Exp Res 1996;20:1196-1201.
129. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA (Ectasy). JAMA 1987;258: 780-781.
130. Hayner GN, McKinney H. MDMA. The dark side of ecstasy. J Psychoact Drugs 1986;18:341-347.
131. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can Med Assoc J 2001;165: 917-928.
132. Regenthal R, Kruger M, Rodolf K, et al. Survival after massive "ecstasy" (MDMA) ingestion. Intensive Care Med 1999;25: 640-641.
133. Hinkelbein J, Gabel A, Volz M, et al. Suicide attempt with high dose ecstasy. Anesthestist 2003;52:51-54.
134. Battaglia G, Yeh SY, O'Hearn E, et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 1987;242: 911-916.
135. Ricaurte GA, Forno LS, Wilson MA, et al. 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260:51-55.
136. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med 1999;340:1443.
137. Kuniyoshi SM, Jankovic J. MDMA and parkinsonism. N Engl J Med 2003;349:96-97.
138. O' Suilleabhain P, Giller C. Rapidly progressive parkinsonism in a self-reported abuser of ecstasy and other drugs. Mov Disord 2003;18:1378-1381.
139. Kish SJ. What is the evidence that ecstasy (MDMA) can cause Parkinson's disease? Mov Disord 2003;18:1219-1223.
140. Ricaurte GA, Yuan J, Hatzidmitrious G, et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (ecstasy). Science 2002;297:2260- 2263.
141. Holden C. Paper on toxic party drug is pulled over vial mix-up. Science 2003;301:1454.
142. Iravani MM, Jackson MJ, Kuoppamaki M, et al. 3,4-Methylene dioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 2003;23: 9107-9115.
143. Borg J, Gershon S. Dose effects of smoked marijuana on human cognitive and motor functions. Psychopharmacolegia 1975;42:211-218.
144. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999;141:385-394.
145. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-48.
146. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13:669-671.
147. Meink HM, Schonle PW, Conrad B. Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236: 120-122.
148. Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62: 1105-1109.
149. Isbell H. Comparison of the reactions produced by psilocybin and LSD-25 in man. Psychopharmacologia 1959;1:29-38.
150. Brouette T, Anton R. Clinical review of inhalants. Am J Addict 2001;10:79-84.
151. Sourindhrin I, Baird JA. Management of solvent misuse: a Glasgow community approach. Br J Addict 1984;79:227-232.
152. Lazar RB, Ho SU, Melon O, et al. Multifocal central nervous system damage caused by toluene abuse. Neurology 1983;33: 1337-1340.
153. Dick F, Sample S, Chen R, et al. Neurological deficits in solvent-exposed painters: a syndrome including impaired color vision, cognitive defects, tremor, and loss of vibration sensation. Q J Med 2000;93:655-661.
154. Maruff P, Burns CB, Tyler P, et al. Neurological and cognitive abnormalities associated with chronic petrol sniffing. Brain 1998;121:1903-1917.
155. McCarron MM, Schultze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1000 cases. Ann Emerg Med 1981;10:237-242.
156. Pradhan SN. Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 1984;8:493-501.
157. Salomon ME. Nicotine and tobacco preparations. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al., editors. Goldfrank's toxicologic emergencies, 6th ed. Stamford, CT: Appleton & Lange; 1998. p 1145-1157.
158. Hernán MA, Takkouche B, Caamaño F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
159. Hernán MA, Zhang SM, Rueda deCastro, et al. Cigarette smoking and incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001;50:780-786.
160. Marder K, Logroscino G. The ever-stimulating association of smoking and coffee and Parkinson's disease. Ann Neurol 2002; 52:261-262.
161. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology 2002;58:581-588.
162. Gorell JM, Rybicki BA, Cole Johnson C, et al. Smoking and Parkinson's disease. A dose-response relationship. Neurology 1999;52:115-119.
163. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002;23:581-594.
164. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001;57:1032-1035.
165. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379: 733-736.
166. Hernán MA, Checkaway H, O'Brien R, et al. MAO B intron 13 and COMT codon 158 polymorphisms, cigarette smoking and the risk of PD. Neurology 2002;58:1381-1387.
167. Checkaway H, Franklin GM, Costa-Mallen P, et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking in Parkinson's disease. Neurology 1998;50:1458-1461.
168. Janson AM, Hedlund PB, Fuxe K, et al. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial mesodiencephalic hemitransection in the cat. Brain Res 1994;655:25-32.
169. Maggio R, Riva M, Vaglini F, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998;71:2439-2446.
170. Prasad C, Ikegami H, Shimizu I, et al. Chronic nicotine intake decelerates aging of nigro-striatal dopaminergic neurons. Life Sci 1994;54:1169-1184.
171. Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Mov Disord 2000;15:1014-1016.
172. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
173. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
174. Geschwantner U, Aston J, Renaud S, et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24:170-172.
175. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
176. Weed MR, Woolverton WL. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. J Pharmacol Exp Ther 1995;275:1367-1374.